Temporal changes in fecal microbiota of patients infected with COVID-19 : a longitudinal cohort
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a multifaceted disease potentially responsible for various clinical manifestations including gastro-intestinal symptoms. Several evidences suggest that the intestine is a critical site of immune cell development, gut microbiota could therefore play a key role in lung immune response. We designed a monocentric longitudinal observational study to describe the gut microbiota profile in COVID-19 patients and compare it to a pre-existing cohort of ventilated non-COVID-19 patients.
METHODS: From March to December 2020, we included patients admitted for COVID-19 in medicine (43 not ventilated) or intensive care unit (ICU) (14 ventilated) with a positive SARS-CoV-2 RT-PCR assay in a respiratory tract sample. 16S metagenomics was performed on rectal swabs from these 57 COVID-19 patients, 35 with one and 22 with multiple stool collections. Nineteen non-COVID-19 ICU controls were also enrolled, among which 14 developed ventilator-associated pneumonia (pneumonia group) and five remained without infection (control group). SARS-CoV-2 viral loads in fecal samples were measured by qPCR.
RESULTS: Although similar at inclusion, Shannon alpha diversity appeared significantly lower in COVID-19 and pneumonia groups than in the control group at day 7. Furthermore, the microbiota composition became distinct between COVID-19 and non-COVID-19 groups. The fecal microbiota of COVID-19 patients was characterized by increased Bacteroides and the pneumonia group by Prevotella. In a distance-based redundancy analysis, only COVID-19 presented significant effects on the microbiota composition. Moreover, patients in ICU harbored increased Campylobacter and decreased butyrate-producing bacteria, such as Lachnospiraceae, Roseburia and Faecalibacterium as compared to patients in medicine. Both the stay in ICU and patient were significant factors affecting the microbiota composition. SARS-CoV-2 viral loads were higher in ICU than in non-ICU patients.
CONCLUSIONS: Overall, we identified distinct characteristics of the gut microbiota in COVID-19 patients compared to control groups. COVID-19 patients were primarily characterized by increased Bacteroides and decreased Prevotella. Moreover, disease severity showed a negative correlation with butyrate-producing bacteria. These features could offer valuable insights into potential targets for modulating the host response through the microbiota and contribute to a better understanding of the disease's pathophysiology.
TRIAL REGISTRATION: CER-VD 2020-00755 (05.05.2020) & 2017-01820 (08.06.2018).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 23(2023), 1 vom: 18. Aug., Seite 537 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galperine, Tatiana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Butyrates |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 20.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-023-08511-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36095295X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36095295X | ||
| 003 | DE-627 | ||
| 005 | 20231226084123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-023-08511-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM36095295X | ||
| 035 | |a (NLM)37596518 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galperine, Tatiana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Temporal changes in fecal microbiota of patients infected with COVID-19 |b a longitudinal cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a multifaceted disease potentially responsible for various clinical manifestations including gastro-intestinal symptoms. Several evidences suggest that the intestine is a critical site of immune cell development, gut microbiota could therefore play a key role in lung immune response. We designed a monocentric longitudinal observational study to describe the gut microbiota profile in COVID-19 patients and compare it to a pre-existing cohort of ventilated non-COVID-19 patients | ||
| 520 | |a METHODS: From March to December 2020, we included patients admitted for COVID-19 in medicine (43 not ventilated) or intensive care unit (ICU) (14 ventilated) with a positive SARS-CoV-2 RT-PCR assay in a respiratory tract sample. 16S metagenomics was performed on rectal swabs from these 57 COVID-19 patients, 35 with one and 22 with multiple stool collections. Nineteen non-COVID-19 ICU controls were also enrolled, among which 14 developed ventilator-associated pneumonia (pneumonia group) and five remained without infection (control group). SARS-CoV-2 viral loads in fecal samples were measured by qPCR | ||
| 520 | |a RESULTS: Although similar at inclusion, Shannon alpha diversity appeared significantly lower in COVID-19 and pneumonia groups than in the control group at day 7. Furthermore, the microbiota composition became distinct between COVID-19 and non-COVID-19 groups. The fecal microbiota of COVID-19 patients was characterized by increased Bacteroides and the pneumonia group by Prevotella. In a distance-based redundancy analysis, only COVID-19 presented significant effects on the microbiota composition. Moreover, patients in ICU harbored increased Campylobacter and decreased butyrate-producing bacteria, such as Lachnospiraceae, Roseburia and Faecalibacterium as compared to patients in medicine. Both the stay in ICU and patient were significant factors affecting the microbiota composition. SARS-CoV-2 viral loads were higher in ICU than in non-ICU patients | ||
| 520 | |a CONCLUSIONS: Overall, we identified distinct characteristics of the gut microbiota in COVID-19 patients compared to control groups. COVID-19 patients were primarily characterized by increased Bacteroides and decreased Prevotella. Moreover, disease severity showed a negative correlation with butyrate-producing bacteria. These features could offer valuable insights into potential targets for modulating the host response through the microbiota and contribute to a better understanding of the disease's pathophysiology | ||
| 520 | |a TRIAL REGISTRATION: CER-VD 2020-00755 (05.05.2020) & 2017-01820 (08.06.2018) | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Gut microbiota | |
| 650 | 4 | |a Gut-lung axis | |
| 650 | 4 | |a Microbiota profiling | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Butyrates |2 NLM | |
| 700 | 1 | |a Choi, Yangji |e verfasserin |4 aut | |
| 700 | 1 | |a Pagani, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Kritikos, Antonios |e verfasserin |4 aut | |
| 700 | 1 | |a Papadimitriou-Olivgeris, Matthaios |e verfasserin |4 aut | |
| 700 | 1 | |a Méan, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Scherz, Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Opota, Onya |e verfasserin |4 aut | |
| 700 | 1 | |a Greub, Gilbert |e verfasserin |4 aut | |
| 700 | 1 | |a Guery, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Bertelli, Claire |e verfasserin |4 aut | |
| 700 | 0 | |a RegCOVID Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Bochud, Pierre-Yves |e investigator |4 oth | |
| 700 | 1 | |a Desgranges, Florian |e investigator |4 oth | |
| 700 | 1 | |a Filippidis, Paraskevas |e investigator |4 oth | |
| 700 | 1 | |a Haefliger, David |e investigator |4 oth | |
| 700 | 1 | |a Kampouri, Eleftheria-Evdokia |e investigator |4 oth | |
| 700 | 1 | |a Manuel, Oriol |e investigator |4 oth | |
| 700 | 1 | |a Munting, Aline |e investigator |4 oth | |
| 700 | 1 | |a Regina, Jean |e investigator |4 oth | |
| 700 | 1 | |a Rochat-Stettler, Laurence |e investigator |4 oth | |
| 700 | 1 | |a Suttels, Veronique |e investigator |4 oth | |
| 700 | 1 | |a Tadini, Eliana |e investigator |4 oth | |
| 700 | 1 | |a Tschopp, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Van Singer, Mathias |e investigator |4 oth | |
| 700 | 1 | |a Viala, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Vollenweider, Peter |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 23(2023), 1 vom: 18. Aug., Seite 537 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:18 |g month:08 |g pages:537 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-023-08511-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 18 |c 08 |h 537 | ||